RCM
GPCR icon

RA Capital Management’s Structure Therapeutics GPCR Stock Holding History

RA Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,517,418
Closed -$42.5M – 78
2025
Q3 		$42.5M Hold
1,517,418
– – 0.52% 31
2025
Q2 		$31.5M Hold
1,517,418
– – 0.53% 31
2025
Q1 		$26.3M Hold
1,517,418
– – 0.44% 36
2024
Q4 		$41.2M Sell
1,517,418
-379,354
-20% -$13.5M 0.55% 37
2024
Q3 		$83.2M Hold
1,896,772
– – 0.96% 29
2024
Q2 		$74.5M Buy
1,896,772
+386,410
+26% +$15.9M 0.99% 29
2024
Q1 		$64.7M Buy
1,510,362
+1,023,530
+210% +$43.2M 0.82% 32
2023
Q4 		$19.8M Buy
+486,832
New +$27.9M 0.31% 49

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RA Capital Management's GPCR Position: Q4 2025 in Review

RA Capital Management sold out of Structure Therapeutics (GPCR) in Q4 2025, closing a stake of 1,517,418 shares — an estimated $42.5M sold.

RA Capital Management first reported a position in GPCR in Q4 2023 and held it in 8 quarters. The position peaked at $83.2M in Q3 2024. 197 funds tracked by Wall St. Rank hold GPCR as of Q4 2025.

  • RA Capital Management reported no remaining Structure Therapeutics position as of Q4 2025 after selling out during the quarter.
  • RA Capital Management sold 1,517,418 Structure Therapeutics shares in Q4 2025, an estimated $42.5M.
  • RA Capital Management first reported a position in Structure Therapeutics in Q4 2023 and held it in 8 quarters.
  • RA Capital Management's Structure Therapeutics position peaked at $83.2M in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2025.

Based on RA Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.